Mesoblast LimitedASX: MSB

Ceasing to be a substantial holder

Aug 3, 2026 at 3:25 AM EDT · Issued by Mesoblast Limited via ASX

Filed with ASX · Aug 3, 2026 at 3:25 AM EDT

On 6ix: 6ix.com/news/ceasing-to-be-a-substantial-holder-300

605 Page 1 03-Aug-2026 To Company Name/Scheme ACN/ARSN 1. Details of substantial holder (1) Name ACN/ARSN (if applicable) The holder ceased to be a substantial holder on 30/07/2026 The previous notice was given to the company on 31/07/2026 The previous notice was dated 29/07/2026 2....

View Attachment

6ix hasn’t read this filing yet.

Mesoblast Limited on 6ix

Earlier from Mesoblast

Becoming a substantial holderJul 31
Quarterly Activities/Appendix 4C Cash Flow ReportJul 29
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product LaunchJul 29
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back PainJul 13
Pivotal Phase 3 Trial in CLBP Achieves 300 Treated PatientsJul 13

Later from Mesoblast

Major Milestone Treatment Completed in P3 Trial for CLBPAug 16
Mesoblast 2026 Full Year Financial Results WebcastAug 24
Notification regarding unquoted securities - MSBAug 24
Appendix 3Y - Philip KrauseAug 24
Preliminary Final Report including Appendix 4EAug 26

All Mesoblast news releases